Kodak says it will manufacture drug ingredients despite Snafu loan
In July, the company struck a $ 765 million deal with the federal government. However, it was suspended after the Securities and Exchange Commission announced an investigation into the deal’s handling.
The Wall Street Journal: Kodak to Advance Drug Ingredient Manufacturing Amid US Loan Problems
Eastman Kodak Co. CEO Jim Continenza has defended his company’s handling of an interrupted US loan and said Kodak will continue to move forward in manufacturing drug ingredients, which it receives. or not government assistance. Mr. Continenza’s comments at WSJ Tech Live Monday follow a tumultuous time for the former photo giant. In July, the company struck a $ 765 million deal with the US government to produce drug ingredients, but its plans quickly collapsed. (Sample, 10/19)
NPR: Large study on Alzheimer’s drugs proceeds with caution, despite pandemic
Medical research was one of the first victims of the COVID-19 pandemic. After cases began to appear around the world, thousands of clinical trials unrelated to COVID-19 were suspended or canceled over fears that participants would be infected. But now some researchers are finding ways to continue despite the coronavirus. “It’s been a struggle of course,” says Joshua Grill, who heads the Institute for Memory Impairment and Neurological Disorders at the University of California, Irvine. “But I think it’s imperative for us to find ways to move forward.” (Hamilton, 10/20)
Stats: CBC Group Creates AffaMed, EverInsight Merger, Plans IPO
With Everest Medicines’ $ 451 million listing now in the rear view mirror, the healthcare-focused CBC Group is paving the way for another holding company for the IPO. But, first, a merger. AffaMed Therapeutics announced last week its merger with EverInsight Therapeutics, another biopharmaceutical company. Both companies were founded by CBC, formerly known as C-Bridge Capital. (Chan, 10/20)
FiercePharma: Antimicrobial Posters: Desktop Content Provider Gives Billboards Safe Refresh Against COVID-19
While many healthcare professionals enjoy the camaraderie of office dining rooms, they probably don’t want additional contagions with their sandwich. Especially during the COVID-19 pandemic. So, Physician’s Weekly, the veteran supplier of pharmaceutical newsletter-style editorial and advertising billboards, decided to take an extra step to make sure their posters were safe. It contracted with a coatings specialist and, starting in September, added antimicrobial surfaces to all of its posters at 23,000 locations. (Bulik, 10/19)
This is part of the KHN Morning Briefing, a summary of coverage of health policies by major news organizations. Sign up for an email subscription.